united therapeutics glp-1 receptor agonist products GLP-ONE + Activator A Closer Look at the

Results The study involved 2,835,398 patients with both NAFLD and type 2 diabetes

Thats how unsafe and unregulated products gain ground

Many people living with Multiple sclerosis are already...

These hormones help the body produce more insulin only when needed and reduce the...

Ahead of the Trump administrations planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the availability of Medicares negotiated price for certain GLP-1 products beginning in 2027, this analysis examines CMSs Medicare Part D claims data from 2019 to 2024 to document the increase in the number of beneficiaries being treated with GLP-1 drugs and the growth in Medicare spending and claims for these drugs.

Obesity is a growing epidemic that affects millions of people worldwide, leading to serious health complications such as heart disease, diabetes, and certain cancers